Symbol
| PCDH17
| contributors: mct - updated : 21-04-2020
|
HGNC name
| protocadherin 17
|
HGNC id
| 14267
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
| --low
|  
|
silenced by DNA methylation in acute myeloid leukemia (AML) | tumoral
|  
|  
| --low
|  
|
by aberrant methylation of PCDH17 gene in high-grade serous ovarian carcinoma | |
Variant & Polymorphism
|
| |
Candidate gene
Marker
| PCDH17 methylation may be a tumor-specific event and can be used as an epigenetic biomarker for nasopharyngeal carcinoma (NPC) | |
PCDH17 methylation in serum is a frequent event in Renal Cell Carcinoma and associated with risk factors of poor outcomes | |
PCDH17 methylation at diagnosis was closely related to poor prognosis and thus could be used as a new biomarker to predict relapse in patients with B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) | |
detection of PCDH17 promoter methylation in serum-derived DNA may be a convenient and noninvasive predictive biomarker in routine clinical practice | Therapy target
| | |